drugset / Trial / NCT02578797

A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study

NCT02578797

Phase 1 Completed 45 enrolled Aragon Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether daily treatment with apalutamide affects the ventricular repolarization in participants with Castration-Resistant Prostate Cancer (CRPC)

Timeline

Start
2015-12-18
Primary completion
2016-09-20
Completion
2022-10-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Apalutamide Small molecule 240 mg Oral